COVID-19 studies:  C19 studies: C19:  IvermectinIVM Vitamin DV.D PXPX FLVFLV PVP-IPI BUBU BHBH BLBL CICI HC QHC Q NZNZ COCO More..
00.250.50.7511.251.51.752+Ruzhentsova (RCT)6%0.94 [0.78-1.14]hosp.3/1122/56Improvement, RR [CI]TreatmentControlUdwadia (RCT)40%0.60 [0.38-0.95]recov. time75 (n)75 (n)Dabbous (RCT)45%0.55 [0.05-5.81]death1/442/48Tau​2 = 0.00; I​2 = 0.0%Early treatment39%0.61 [0.40-0.95]4/2314/17939% improvementCai69%0.31 [0.10-0.96]pneumonia35 (n)45 (n)Improvement, RR [CI]TreatmentControlIvashchenko (RCT)46%0.54 [0.33-0.88]viral+15/4014/20Pushkar (RCT)14%0.86 [0.74-0.99]no recov.73/10085/100Solaymani-.. (RCT)-19%1.19 [0.70-2.04]death26/19021/183OT​1Zhao (RCT)59%0.41 [0.18-0.93]viral+7/369/19Aghajani26%0.74 [0.43-1.27]death40 (n)951 (n)Almoosa-42%1.42 [0.90-2.25]death33/11024/116Tau​2 = 0.09; I​2 = 62.9%Late treatment21%0.79 [0.58-1.06]154/551153/1,43421% improvementAll studies23%0.77 [0.60-0.98]158/782157/1,61323% improvement10 favipiravir COVID-19 studiesc19favipiravir.com Aug 29, 20211 OT: comparison with other treatmentTau​2 = 0.06; I​2 = 50.9%; Z = 2.09Effect extraction pre-specifiedLower RiskIncreased Risk 00.250.50.7511.251.51.752+Dabbous (RCT)45%0.55 [0.05-5.81]1/442/48Improvement, RR [CI]TreatmentControlTau​2 = 0.00; I​2 = 0.0%Early treatment45%0.55 [0.05-5.81]1/442/4845% improvementSolaymani-.. (RCT)-19%1.19 [0.70-2.04]26/19021/183OT​1Improvement, RR [CI]TreatmentControlAghajani26%0.74 [0.43-1.27]40 (n)951 (n)Almoosa-42%1.42 [0.90-2.25]33/11024/116Tau​2 = 0.05; I​2 = 40.9%Late treatment-10%1.10 [0.75-1.61]59/34045/1,250-10% improvementAll studies-9%1.09 [0.78-1.53]60/38447/1,298-9% improvement4 favipiravir COVID-19 mortality resultsc19favipiravir.com Aug 29, 20211 OT: comparison with other treatmentTau​2 = 0.02; I​2 = 19.6%; Z = 0.49Lower RiskIncreased Risk 00.250.50.7511.251.51.752+Solaymani-.. (RCT)-19%1.19 [0.73-1.94]31/19025/183OT​1Improvement, RR [CI]TreatmentControlAlmoosa-90%1.90 [1.11-3.26]110 (n)116 (n)Tau​2 = 0.04; I​2 = 36.1%Late treatment-48%1.48 [0.94-2.33]31/30025/299-48% improvementAll studies-48%1.48 [0.94-2.33]31/30025/299-48% improvement2 favipiravir COVID-19 ICU resultsc19favipiravir.com Aug 29, 20211 OT: comparison with other treatmentTau​2 = 0.04; I​2 = 36.1%; Z = 1.70Lower RiskIncreased Risk 00.250.50.7511.251.51.752+Ruzhentsova (RCT)6%0.94 [0.78-1.14]hosp.3/1122/56Improvement, RR [CI]TreatmentControlDabbous (RCT)16%0.84 [0.69-1.01]hosp. time44 (n)48 (n)Tau​2 = 0.00; I​2 = 0.0%Early treatment16%0.84 [0.70-1.01]3/1562/10416% improvementIvashchenko (RCT)-300%4.00 [0.20-79.6]hosp.2/400/20Improvement, RR [CI]TreatmentControlTau​2 = 0.00; I​2 = 0.0%Late treatment-300%4.00 [0.20-79.6]2/400/20-300% improvementAll studies16%0.84 [0.70-1.01]5/1962/12416% improvement3 favipiravir COVID-19 hospitalization resultsc19favipiravir.com Aug 29, 2021Tau​2 = 0.00; I​2 = 0.0%; Z = 1.81Lower RiskIncreased Risk 00.250.50.7511.251.51.752+Ruzhentsova (RCT)6%0.94 [0.78-1.14]hosp.3/1122/56Improvement, RR [CI]TreatmentControlDabbous (RCT)45%0.55 [0.05-5.81]death1/442/48Tau​2 = 0.00; I​2 = 0.0%Early treatment23%0.77 [0.19-3.18]4/1564/10423% improvementSolaymani-.. (RCT)-19%1.19 [0.70-2.04]death26/19021/183OT​1Improvement, RR [CI]TreatmentControlAghajani26%0.74 [0.43-1.27]death40 (n)951 (n)Almoosa-42%1.42 [0.90-2.25]death33/11024/116Tau​2 = 0.05; I​2 = 40.9%Late treatment-10%1.10 [0.75-1.61]59/34045/1,250-10% improvementAll studies-10%1.10 [0.82-1.46]63/49649/1,354-10% improvement5 favipiravir COVID-19 serious outcomesc19favipiravir.com Aug 29, 20211 OT: comparison with other treatmentTau​2 = 0.00; I​2 = 0.0%; Z = 0.64Effect extraction pre-specifiedLower RiskIncreased Risk 00.250.50.7511.251.51.752+Ruzhentsova (RCT)22%0.78 [0.92-1.79]112 (n)56 (n)Improvement, RR [CI]TreatmentControlUdwadia (RCT)29%0.71 [0.46-1.10]75 (n)75 (n)Tau​2 = 0.00; I​2 = 0.0%Early treatment25%0.75 [0.57-0.99]0/1870/13125% improvementCai71%0.29 [0.10-0.86]35 (n)45 (n)Improvement, RR [CI]TreatmentControlIvashchenko (RCT)46%0.54 [0.33-0.88]15/4014/20Pushkar (RCT)90%0.10 [0.02-0.40]2/10021/100Zhao (RCT)59%0.41 [0.18-0.93]7/369/19Tau​2 = 0.16; I​2 = 46.0%Late treatment65%0.35 [0.20-0.64]24/21144/18465% improvementAll studies48%0.52 [0.35-0.77]24/39844/31548% improvement6 favipiravir COVID-19 viral clearance resultsc19favipiravir.com Aug 29, 2021Tau​2 = 0.12; I​2 = 58.1%; Z = 3.30Lower RiskIncreased Risk 00.250.50.7511.251.51.752+Ruzhentsova (RCT)6%0.94 [0.78-1.14]hosp.3/1122/56Improvement, RR [CI]TreatmentControlUdwadia (RCT)40%0.60 [0.38-0.95]recov. time75 (n)75 (n)Dabbous (RCT)45%0.55 [0.05-5.81]death1/442/48Tau​2 = 0.00; I​2 = 0.0%Early treatment39%0.61 [0.40-0.95]4/2314/17939% improvementIvashchenko (RCT)46%0.54 [0.33-0.88]viral+15/4014/20Improvement, RR [CI]TreatmentControlPushkar (RCT)14%0.86 [0.74-0.99]no recov.73/10085/100Solaymani-.. (RCT)-19%1.19 [0.70-2.04]death26/19021/183OT​1Zhao (RCT)59%0.41 [0.18-0.93]viral+7/369/19Tau​2 = 0.08; I​2 = 61.8%Late treatment25%0.75 [0.52-1.07]121/366129/32225% improvementAll studies27%0.73 [0.57-0.95]125/597133/50127% improvement7 favipiravir COVID-19 Randomized Controlled Trialsc19favipiravir.com Aug 29, 20211 OT: comparison with other treatmentTau​2 = 0.04; I​2 = 38.4%; Z = 2.36Effect extraction pre-specifiedLower RiskIncreased Risk 00.250.50.7511.251.51.752+Dabbous (RCT)45%0.55 [0.05-5.81]1/442/48Improvement, RR [CI]TreatmentControlTau​2 = 0.00; I​2 = 0.0%Early treatment45%0.55 [0.05-5.81]1/442/4845% improvementSolaymani-.. (RCT)-19%1.19 [0.70-2.04]26/19021/183OT​1Improvement, RR [CI]TreatmentControlTau​2 = 0.00; I​2 = 0.0%Late treatment-19%1.19 [0.70-2.04]26/19021/183-19% improvementAll studies-15%1.15 [0.68-1.94]27/23423/231-15% improvement2 favipiravir COVID-19 RCT mortality resultsc19favipiravir.com Aug 29, 20211 OT: comparison with other treatmentTau​2 = 0.00; I​2 = 0.0%; Z = 0.51Lower RiskIncreased Risk 00.250.50.7511.251.51.752+Udwadia (RCT)40%0.60 [0.38-0.95]recov. time75 (n)75 (n)Improvement, RR [CI]TreatmentControlDabbous (RCT)45%0.55 [0.05-5.81]death1/442/48Tau​2 = 0.00; I​2 = 0.0%Early treatment40%0.60 [0.38-0.94]1/1192/12340% improvementCai69%0.31 [0.10-0.96]pneumonia35 (n)45 (n)Improvement, RR [CI]TreatmentControlIvashchenko (RCT)46%0.54 [0.33-0.88]viral+15/4014/20Solaymani-.. (RCT)-19%1.19 [0.70-2.04]death26/19021/183OT​1Zhao (RCT)59%0.41 [0.18-0.93]viral+7/369/19Aghajani26%0.74 [0.43-1.27]death40 (n)951 (n)Almoosa-42%1.42 [0.90-2.25]death33/11024/116Tau​2 = 0.20; I​2 = 68.9%Late treatment27%0.73 [0.47-1.14]81/45168/1,33427% improvementAll studies28%0.72 [0.50-1.02]82/57070/1,45728% improvement8 favipiravir COVID-19 peer reviewed trialsc19favipiravir.com Aug 29, 20211 OT: comparison with other treatmentTau​2 = 0.14; I​2 = 60.1%; Z = 1.83Effect extraction pre-specifiedLower RiskIncreased Risk 00.250.50.7511.251.51.752+Ruzhentsova (RCT)6%0.94 [0.78-1.14]hosp.3/1122/56Improvement, RR [CI]TreatmentControlRuzhentsova (RCT)39%0.61 [0.43-0.88]no recov.112 (n)56 (n)Ruzhentsova (RCT)22%0.78 [0.92-1.79]viral+112 (n)56 (n)Udwadia (RCT)40%0.60 [0.38-0.95]recov. time75 (n)75 (n)Udwadia (RCT)29%0.71 [0.46-1.10]viral time75 (n)75 (n)Dabbous (RCT)45%0.55 [0.05-5.81]death1/442/48Dabbous (RCT)88%0.12 [0.01-2.08]ventilation0/444/48Dabbous (RCT)16%0.84 [0.69-1.01]hosp. time44 (n)48 (n)Cai69%0.31 [0.10-0.96]pneumonia35 (n)45 (n)Cai71%0.29 [0.10-0.86]viral+35 (n)45 (n)Ivashchenko (RCT)46%0.54 [0.33-0.88]viral+15/4014/20Ivashchenko (RCT)62%0.38 [0.09-1.52]viral+3/404/20Ivashchenko (RCT)-67%1.67 [0.52-5.39]no disch.10/403/20Ivashchenko (RCT)-300%4.00 [0.20-79.6]hosp.2/400/20Pushkar (RCT)14%0.86 [0.74-0.99]no recov.73/10085/100Pushkar (RCT)33%0.67 [0.54-0.82]recov. time100 (n)100 (n)Pushkar (RCT)45%0.55 [0.42-0.72]no recov.40/10073/100Pushkar (RCT)20%0.80 [0.64-1.00]recov. time100 (n)100 (n)Pushkar (RCT)70%0.30 [0.16-0.58]no disch.10/10033/100Pushkar (RCT)27%0.73 [0.63-0.86]no recov.66/10090/100Pushkar (RCT)33%0.67 [0.50-0.89]pneumonia40/10060/100Pushkar (RCT)90%0.10 [0.02-0.40]viral+2/10021/100Solaymani-.. (RCT)-19%1.19 [0.70-2.04]death26/19021/183OT​1Solaymani-.. (RCT)-53%1.53 [0.86-2.71]ventilation27/19017/183OT​1Solaymani-.. (RCT)-19%1.19 [0.73-1.94]ICU31/19025/183OT​1Zhao (RCT)59%0.41 [0.18-0.93]viral+7/369/19Zhao (RCT)52%0.48 [0.25-0.91]viral time36 (n)19 (n)Aghajani26%0.74 [0.43-1.27]death40 (n)951 (n)Almoosa-42%1.42 [0.90-2.25]death33/11024/116Almoosa-90%1.90 [1.11-3.26]ICU110 (n)116 (n)Almoosa-11%1.11 [0.96-1.29]recov. time110 (n)116 (n)favipiravir COVID-19 outcomesc19favipiravir.com Aug 29, 2021Lower RiskIncreased Risk
Please send us corrections, updates, or comments. Vaccines and treatments are both extremely valuable and complementary. All practical, effective, and safe means should be used. Elimination of COVID-19 is a race against viral evolution. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. Denying the efficacy of any method increases the risk of COVID-19 becoming endemic; and increases mortality, morbidity, and collateral damage. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. Treatment protocols for physicians are available from the FLCCC.
  or use drag and drop   
Thanks for your feedback! Please search before submitting papers and note that studies are listed under the date they were first available, which may be the date of an earlier preprint.
Submit    
Aspirin
Bamlanivimab
Bromhexine
Budesonide
Casirivimab/i..
Colchicine
Curcumin
Favipiravir
Fluvoxamine
Hydroxychloro..
Iota-carragee..
Ivermectin
Melatonin
Molnupiravir
Nigella Sativa
Nitazoxanide
Povidone-Iod..
Probiotics
Proxalutamide
Quercetin
Remdesivir
Sotrovimab
Vitamin C
Vitamin D
Zinc

Other
Feedback
Home